United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Healthcare Industry News Humacyte begins phase 2 Humacyl vascular trauma trial Humacyl vascular trauma trial : Humacyte, a regenerative medical technology company, has started a phase 2 clinical trial… bypharmanewsdailyNovember 10, 2018
